Taiga Biotechnologies

Taiga Biotechnologies, Inc. is a clinical stage biotechnology company located in Aurora, Colorado. Founded as a privately held corporation, Taiga Biotechnologies employs 4 individuals. Taiga Biotechnologies focuses on developing innovative therapies in the fields of immunotherapy and regenerative medicine. Their primary focus is harnessing the power of the immune system to combat solid tumors, infectious diseases, and improve blood stem cell transplantation. Their Cell-Based Immunotherapy utilizes a patient's own immune cells, treated ex vivo, to fight against various diseases. Taiga Biotechnologies' Cell-Based Immunotherapy technology offers several advantages over traditional approaches. Their methods do not require laboratory expansion of T-cells, limit responses based on engineered specificity, or necessitate genetic modification of T-cells. Additionally, their Bone Marrow Engraftment Enhancer (BMEE) program aims to enhance the engraftment of hematopoietic stem and progenitor cells during allogeneic hematopoietic stem cell transplants, ultimately increasing the chances of long-term survival for recipients. For further information, please visit Taiga Biotechnologies' website at taigabiotech.com.